UCB, a global biopharmaceutical company, today announced the CHMP (Committee for Medicinal Products for Human Use) has issued a positive opinion for the self-administration of RYSTIGGO® ...

It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and ...

Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Induces potent and long-lasting immune responses to defined antigens or whole pathogens (particles), mainly through the ...

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...

Masaaki Tamura, age 75, passed away surrounded by family at the University of Kansas Medical Center, Kansas City, KS, on Thursday, January 16, 2025, following a sudden illness.

Portsmouth is making strides in tackling air pollution, with compliance achieved for key pollutants, but traffic-related ...

Phase III Vivacity-MG3 trial shows that nipocalimab, an investigational FcRn blocker, significantly the improves symptoms of generalized myasthenia gravis with a manageable safety profile.

We recently published a list of 12 High Growth International Stocks to Invest in Now. In this article, we are going to take a look at where argenx SE (NASDAQ:ARGX) stands against other high growth ...

KFDA approves Argenxs Vibgart for severe myasthenia gravis treatment KFDA greenlights innovative therapy for muscle weakness ...